Ellie Becker, | |
1455 Dixon Ave, Lafayette, CO 80026-8879 | |
(303) 443-8500 | |
Not Available |
Full Name | Ellie Becker |
---|---|
Gender | Female |
Speciality | Counselor - Mental Health |
Location | 1455 Dixon Ave, Lafayette, Colorado |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1417589490 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Ellie Becker, 1455 Dixon Ave, Lafayette, CO 80026-8879 Ph: () - | Ellie Becker, 1455 Dixon Ave, Lafayette, CO 80026-8879 Ph: (303) 443-8500 |
News Archive
Japanese researchers have developed and tested a prototype device - wearable on the fingertips - that incorporates the concept of 'light touch' to enhance the sense of balance. If widely implemented, the device should significantly reduce incidence of falls amongst seniors.
Sony has released a new, more user-friendly workflow version of its vendor-neutral medical imaging platform, NUCLeUS.
The sporting world lost two young athletes this month to sudden cardiac death. Preliminary autopsy reports indicate that Chicago Bears defensive end Gaines Adams, 26, and Southern Indiana center Jeron Lewis, 21, both had enlarged hearts at the time of their death.
In a recent study published in Tobacco Control, researchers at the University of Ottawa Heart Institute have demonstrated the cost-effectiveness of the Ottawa Model for Smoking Cessation (OMSC), an intervention that includes in-hospital counseling, pharmacotherapy and post-hospital follow-up, compared to usual care among smokers hospitalized with acute myocardial infarction, unstable angina, heart failure, and chronic obstructive pulmonary disease.
Onyx Pharmaceuticals, Inc. today announced results from the Phase 3 trial GRID (GIST – Regorafenib in Progressive Disease) evaluating the investigational compound regorafenib (BAY 73-4506), a Bayer-owned compound, for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib.
› Verified 1 days ago